Kolibitor Solution for Infusion contains a combination of Sulfamethoxazole (80 mg/ml) and Trimethoprim (16 mg/ml), which act synergistically as a potent antimicrobial agent. This formulation is indicated for the treatment of a variety of bacterial infections caused by susceptible strains, including urinary tract infections, respiratory tract infections, gastrointestinal infections, and certain types of systemic infections. Sulfamethoxazole, a sulfonamide antibiotic, inhibits bacterial synthesis of dihydrofolic acid, while Trimethoprim blocks the subsequent step of tetrahydrofolic acid formation, resulting in a sequential blockade of folic acid synthesis essential for bacterial growth and replication. Kolibitor Solution for Infusion is administered intravenously, allowing for rapid and effective delivery in patients unable to take oral medications or requiring high systemic concentrations. Dosage and duration of therapy should be tailored according to the severity of infection, patient weight, renal function, and clinical response. Caution is advised in patients with hypersensitivity to sulfonamides or trimethoprim, as well as those with severe renal or hepatic impairment. Monitoring for adverse effects such as hypersensitivity reactions, hematological abnormalities, and renal function alterations is recommended during therapy. This combination provides a broad-spectrum antibacterial effect, making it suitable for hospital use in managing serious infections.